Equillium (EQ) Return on Capital Employed (2018 - 2026)
Equillium (EQ) reported Return on Capital Employed of 3.27% for Q1 2026, up 4748.0% year-over-year from 0.07% in Q1 2025, and up 78.94% quarter-over-quarter from 15.55% in Q4 2025.
Equillium (EQ) Return on Capital Employed (2018 - 2026) Analysis & Trends
Equillium (EQ) has 9 years of Return on Capital Employed data on file, last reported at 3.27% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 3.27%, up 4748.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 3.27% (up 4748.0% YoY), and the FY2025 annual result was 18.22%, down 1312.0% from the prior year.
- Return on Capital Employed climbed to 3.27% in Q1 2026 per EQ's latest filing, from 15.55% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 3.27% in Q1 2026 and troughed at 197.14% in Q4 2022.
- A 5-year average of 75.85% and a median of 53.13% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2023: Return on Capital Employed sank 14992 bps in 2022, then jumped 15119 bps in 2023.
- A 5-year view of Return on Capital Employed shows it stood at 197.14% in 2022, then soared by 71 bps to 57.39% in 2023, then soared by 88 bps to 6.83% in 2024, then tumbled by 128 bps to 15.55% in 2025, then jumped by 79 bps to 3.27% in 2026.
- Business Quant data shows EQ's Return on Capital Employed at 3.27% in Q1 2026, 15.55% in Q4 2025, and 87.04% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Equillium | 293.17 Mn | 232.78 Mn | - | -3.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.27% |
| Dec 31, 2025 | -15.55% |
| Sep 30, 2025 | -87.04% |
| Jun 30, 2025 | -188.59% |
| Mar 31, 2025 | -50.75% |
| Dec 31, 2024 | -6.83% |
| Sep 30, 2024 | -24.53% |
| Jun 30, 2024 | -42.12% |
| Mar 31, 2024 | -53.13% |
| Dec 31, 2023 | -57.39% |
| Sep 30, 2023 | -32.23% |
| Jun 30, 2023 | -47.17% |
| Mar 31, 2023 | -66.97% |
| Dec 31, 2022 | -197.14% |
| Sep 30, 2022 | -183.41% |
| Jun 30, 2022 | -133.79% |
| Mar 31, 2022 | -99.57% |
| Dec 31, 2021 | -47.22% |
| Sep 30, 2021 | -41.15% |
| Jun 30, 2021 | -33.58% |